PT1347760E - Composicoes farmaceuticas de agonista do receptor de nmda - Google Patents

Composicoes farmaceuticas de agonista do receptor de nmda

Info

Publication number: PT1347760E
Authority: PT; Portugal
Prior art keywords: receptor agonist; nmda receptor; pharmaceutical compounds; pharmaceutical; compounds
Prior art date: 2000-12-13

Application number

PT01270205T

Other languages

English (en)

Inventor

Yesook Kim

Jinyang Hong

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-12-13

Filing date

2001-12-05

Publication date

2005-09-30

2001-12-05 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2005-09-30 Publication of PT1347760E publication Critical patent/PT1347760E/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Epidemiology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Dermatology (AREA)
Psychology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Diabetes (AREA)
Inorganic Chemistry (AREA)
Urology & Nephrology (AREA)
Addiction (AREA)
Vascular Medicine (AREA)
Hospice & Palliative Care (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Hematology (AREA)
Obesity (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Hydrogenated Pyridines (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PT01270205T 2000-12-13 2001-12-05 Composicoes farmaceuticas de agonista do receptor de nmda PT1347760E (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US25537200P	2000-12-13	2000-12-13

Publications (1)

Publication Number	Publication Date
PT1347760E true PT1347760E (pt)	2005-09-30

Family

ID=22968017

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT01270205T PT1347760E (pt)	2000-12-13	2001-12-05	Composicoes farmaceuticas de agonista do receptor de nmda

Country Status (41)

Country	Link
US (2)	US6635270B2 (pt)
EP (1)	EP1347760B1 (pt)
JP (1)	JP2004515529A (pt)
KR (1)	KR100533407B1 (pt)
CN (1)	CN1273135C (pt)
AP (1)	AP1235A (pt)
AR (1)	AR035607A1 (pt)
AT (1)	ATE296629T1 (pt)
AU (2)	AU1845402A (pt)
BG (1)	BG107788A (pt)
BR (1)	BR0116085A (pt)
CA (1)	CA2431172A1 (pt)
CZ (1)	CZ20031543A3 (pt)
DE (1)	DE60111265T2 (pt)
DO (1)	DOP2001000300A (pt)
DZ (1)	DZ3484A1 (pt)
EA (1)	EA006489B1 (pt)
EC (1)	ECSP034655A (pt)
EE (1)	EE200300284A (pt)
ES (1)	ES2239648T3 (pt)
GE (1)	GEP20053568B (pt)
HR (1)	HRP20030473A2 (pt)
HU (1)	HUP0400645A2 (pt)
IL (1)	IL155810A0 (pt)
IS (1)	IS6811A (pt)
MA (1)	MA26970A1 (pt)
MX (1)	MXPA03005257A (pt)
NO (1)	NO20032678L (pt)
NZ (1)	NZ525742A (pt)
OA (1)	OA12414A (pt)
PA (1)	PA8534901A1 (pt)
PE (1)	PE20020710A1 (pt)
PL (1)	PL362080A1 (pt)
PT (1)	PT1347760E (pt)
SK (1)	SK6982003A3 (pt)
TN (1)	TNSN01173A1 (pt)
UA (1)	UA73619C2 (pt)
UY (1)	UY27068A1 (pt)
WO (1)	WO2002047685A2 (pt)
YU (1)	YU41103A (pt)
ZA (1)	ZA200303892B (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HRP20150037T4 (hr)	2003-04-08	2022-09-02	Progenics Pharmaceuticals, Inc.	Farmaceutske formulacije koje sadrže metilnaltrekson
TW200800959A (en) *	2005-06-10	2008-01-01	Wyeth Corp	Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor
TW200808740A (en) *	2006-06-09	2008-02-16	Wyeth Corp	Succinate salts of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline and crystalline forms thereof
TW200811144A (en) *	2006-06-09	2008-03-01	Wyeth Corp	Crystalline forms of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline
TW200808741A (en) *	2006-06-09	2008-02-16	Wyeth Corp	6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline hydrochloric acid salts
TWI489984B (zh)	2006-08-04	2015-07-01	Wyeth Corp	用於非經腸道傳輸化合物之配方及其用途
US20080262228A1 (en) *	2006-11-28	2008-10-23	Wyeth	Metabolites of 5-fluoro-8- quinoline and methods of preparation and uses thereof
TW200901974A (en)	2007-01-16	2009-01-16	Wyeth Corp	Compounds, compositions, and methods of making and using them
CN101317844B (zh) *	2007-06-08	2010-11-17	章劲夫	化合物(+)-5-甲基-10，11-二氢-5H-二苯并〔a，d〕环庚烯-5，10-亚胺在制备避孕药物中的应用
BRPI0918868B8 (pt)	2008-09-18	2021-05-25	Naurex Inc	compostos moduladores do receptor de nmda e composições compreendendo os mesmos
US8951968B2 (en)	2009-10-05	2015-02-10	Northwestern University	Methods of treating depression and other related diseases
KR101692275B1 (ko)	2010-02-11	2017-01-04	노오쓰웨스턴 유니버시티	２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
EP2542254B1 (en)	2010-02-11	2018-09-26	Northwestern University	Nmda receptor agonists and uses thereof
CN102586243A (zh) *	2012-03-08	2012-07-18	中国人民解放军军事医学科学院放射与辐射医学研究所	一种预防电磁辐射致脑损伤的标志物
US20140206667A1 (en)	2012-11-14	2014-07-24	Michela Gallagher	Methods and compositions for treating schizophrenia
WO2014120789A1 (en)	2013-01-29	2014-08-07	Naurex, Inc.	Spiro-lactam nmda receptor modulators and uses thereof
SG11201505862TA (en)	2013-01-29	2015-08-28	Naurex Inc	Spiro-lactam nmda receptor modulators and uses thereof
LT3514158T (lt)	2013-01-29	2023-02-10	Aptinyx Inc.	Spirolaktaminiai nmda receptoriaus moduliatoriai ir jų panaudojimas
PE20151427A1 (es)	2013-01-29	2015-10-10	Naurex Inc	Moduladores de receptores nmda de espiro-lactama y sus usos
MX2015009773A (es)	2013-01-29	2016-08-05	Aptinyx Inc	Moduladores de receptores nmda de espiro-lactama y sus usos.
WO2015099381A1 (ko)	2013-12-23	2015-07-02	주식회사 삼양바이오팜	팔로노세트론을 함유하는 약학 조성물
WO2017201285A1 (en)	2016-05-19	2017-11-23	Aptinyx Inc.	Spiro-lactam nmda receptor modulators and uses thereof
KR102128675B1 (ko)	2016-05-19	2020-06-30	앱티닉스 인크.	스피로-락탐 nmda 수용체 조정제 및 그의 용도
WO2018026792A1 (en)	2016-08-01	2018-02-08	Aptinyx Inc.	Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
AU2017306164B2 (en)	2016-08-01	2021-10-21	Tenacia Biotechnology (Hong Kong) Co., Limited	Spiro-lactam NMDA modulators and methods of using same
EP3490974B1 (en)	2016-08-01	2023-12-06	Tenacia Biotechnology (Hong Kong) Co., Limited	Spiro-lactam nmda receptor modulators and uses thereof
SG10202101055VA (en)	2016-08-01	2021-03-30	Aptinyx Inc	Spiro-lactam nmda receptor modulators and uses thereof
IL286107B2 (en)	2016-08-01	2024-09-01	Aptinyx Inc	Spiro-lactam nmda receptor modulators and usesthereof
JP7210599B2 (ja)	2018-01-31	2023-01-23	アプティニックスインコーポレイテッド	スピロラクタム系ｎｍｄａ受容体修飾因子およびその使用
US12012413B2 (en)	2019-11-11	2024-06-18	Tenacia Biotechnology (Hong Kong) Co., Limited	Methods of treating painful diabetic peripheral neuropathy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5272160A (en) *	1989-05-17	1993-12-21	Pfizer Inc	2-piperidino-1-alkanol derivatives as antiischemic agents
US5710168A (en) *	1991-10-23	1998-01-20	Pfizer Inc.	2-piperidino-1-alkanol derivatives as neuroprotective agents
HUP9802862A3 (en) *	1995-08-11	1999-05-28	Pfizer	(1s,2s)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanolmethanesulfonate trihydrate and pharmaceutical compositions containing it for treating cns disorders
TW450807B (en) *	1995-09-15	2001-08-21	Pfizer	Pharmaceutical compositions for treating tinnitus comprising neuroprotective agents

2001
- 2001-05-12 UA UA2003065485A patent/UA73619C2/uk unknown
- 2001-12-05 HU HU0400645A patent/HUP0400645A2/hu unknown
- 2001-12-05 PL PL01362080A patent/PL362080A1/xx not_active Application Discontinuation
- 2001-12-05 US US10/010,827 patent/US6635270B2/en not_active Expired - Fee Related
- 2001-12-05 HR HR20030473A patent/HRP20030473A2/hr not_active Application Discontinuation
- 2001-12-05 CZ CZ20031543A patent/CZ20031543A3/cs unknown
- 2001-12-05 EA EA200300514A patent/EA006489B1/ru not_active IP Right Cessation
- 2001-12-05 MX MXPA03005257A patent/MXPA03005257A/es active IP Right Grant
- 2001-12-05 OA OA1200300145A patent/OA12414A/en unknown
- 2001-12-05 IL IL15581001A patent/IL155810A0/xx unknown
- 2001-12-05 DE DE60111265T patent/DE60111265T2/de not_active Expired - Fee Related
- 2001-12-05 EP EP01270205A patent/EP1347760B1/en not_active Expired - Lifetime
- 2001-12-05 AU AU1845402A patent/AU1845402A/xx active Pending
- 2001-12-05 NZ NZ525742A patent/NZ525742A/en unknown
- 2001-12-05 KR KR10-2003-7007874A patent/KR100533407B1/ko not_active Expired - Fee Related
- 2001-12-05 GE GE5171A patent/GEP20053568B/en unknown
- 2001-12-05 CA CA002431172A patent/CA2431172A1/en not_active Abandoned
- 2001-12-05 AT AT01270205T patent/ATE296629T1/de not_active IP Right Cessation
- 2001-12-05 EE EEP200300284A patent/EE200300284A/xx unknown
- 2001-12-05 JP JP2002549256A patent/JP2004515529A/ja active Pending
- 2001-12-05 YU YU41103A patent/YU41103A/sh unknown
- 2001-12-05 PT PT01270205T patent/PT1347760E/pt unknown
- 2001-12-05 WO PCT/IB2001/002359 patent/WO2002047685A2/en not_active Ceased
- 2001-12-05 DZ DZ013484A patent/DZ3484A1/fr active
- 2001-12-05 SK SK698-2003A patent/SK6982003A3/sk unknown
- 2001-12-05 CN CNB018203922A patent/CN1273135C/zh not_active Expired - Fee Related
- 2001-12-05 BR BR0116085-0A patent/BR0116085A/pt not_active IP Right Cessation
- 2001-12-05 AU AU2002218454A patent/AU2002218454B2/en not_active Ceased
- 2001-12-05 ES ES01270205T patent/ES2239648T3/es not_active Expired - Lifetime
- 2001-12-10 DO DO2001000300A patent/DOP2001000300A/es unknown
- 2001-12-11 PE PE2001001235A patent/PE20020710A1/es not_active Application Discontinuation
- 2001-12-11 AR ARP010105748A patent/AR035607A1/es unknown
- 2001-12-12 UY UY27068A patent/UY27068A1/es not_active Application Discontinuation
- 2001-12-12 TN TNTNSN01173A patent/TNSN01173A1/fr unknown
- 2001-12-13 AP APAP/P/2001/002376A patent/AP1235A/en active
- 2001-12-13 PA PA20018534901A patent/PA8534901A1/es unknown
2003
- 2003-05-08 IS IS6811A patent/IS6811A/is unknown
- 2003-05-09 BG BG107788A patent/BG107788A/bg unknown
- 2003-05-20 ZA ZA200303892A patent/ZA200303892B/en unknown
- 2003-06-03 MA MA27191A patent/MA26970A1/fr unknown
- 2003-06-12 NO NO20032678A patent/NO20032678L/no not_active Application Discontinuation
- 2003-06-13 EC EC2003004655A patent/ECSP034655A/es unknown
- 2003-08-19 US US10/643,441 patent/US20040039022A1/en not_active Abandoned

Also Published As

Publication number	Publication date
HRP20030473A2 (en)	2005-04-30
US6635270B2 (en)	2003-10-21
ES2239648T3 (es)	2005-10-01
ECSP034655A (es)	2003-07-25
EE200300284A (et)	2003-10-15
NZ525742A (en)	2005-07-29
CA2431172A1 (en)	2002-06-20
TNSN01173A1 (fr)	2005-11-10
AU2002218454B2 (en)	2005-10-27
JP2004515529A (ja)	2004-05-27
EP1347760A2 (en)	2003-10-01
ATE296629T1 (de)	2005-06-15
KR100533407B1 (ko)	2005-12-02
SK6982003A3 (en)	2004-08-03
DE60111265T2 (de)	2006-05-04
UY27068A1 (es)	2002-07-31
AP2001002376A0 (en)	2001-12-31
AP1235A (en)	2004-01-06
MA26970A1 (fr)	2004-12-20
WO2002047685A2 (en)	2002-06-20
BG107788A (bg)	2004-01-30
NO20032678D0 (no)	2003-06-12
EA006489B1 (ru)	2005-12-29
US20040039022A1 (en)	2004-02-26
HK1059575A1 (en)	2004-07-09
PA8534901A1 (es)	2002-08-26
NO20032678L (no)	2003-06-12
YU41103A (sh)	2006-05-25
EA200300514A1 (ru)	2003-10-30
EP1347760B1 (en)	2005-06-01
AR035607A1 (es)	2004-06-16
ZA200303892B (en)	2004-05-20
DZ3484A1 (fr)	2002-06-20
IS6811A (is)	2003-05-08
IL155810A0 (en)	2003-12-23
US20020111366A1 (en)	2002-08-15
PL362080A1 (en)	2004-10-18
PE20020710A1 (es)	2002-08-09
HUP0400645A2 (hu)	2004-06-28
DE60111265D1 (de)	2005-07-07
OA12414A (en)	2006-04-18
GEP20053568B (en)	2005-07-11
CZ20031543A3 (cs)	2004-06-16
KR20030070060A (ko)	2003-08-27
AU1845402A (en)	2002-06-24
WO2002047685A3 (en)	2002-08-15
MXPA03005257A (es)	2003-09-25
DOP2001000300A (es)	2002-05-30
CN1479617A (zh)	2004-03-03
BR0116085A (pt)	2003-12-23
UA73619C2 (en)	2005-08-15
CN1273135C (zh)	2006-09-06

Publication	Publication Date	Title
PT1347760E (pt)	2005-09-30	Composicoes farmaceuticas de agonista do receptor de nmda
PL365377A1 (en)	2005-01-10	Amide derivatives as nmda receptor antagonists
ATE431145T1 (de)	2009-05-15	Missbrauchssichere orale opioid-agonist zubereitungen
DK1446379T3 (da)	2009-07-27	Arylanilin-beta2-adrenergiske receptoragonister
NO20030418L (no)	2003-01-27	Nytt farmasöytisk preparat
DE60132799D1 (de)	2008-03-27	Peroxisom proliferator aktivierten rezeptor alpha agonisten
PT1221952E (pt)	2005-08-31	Utilizacao de um agonista dos receptores canabinoides centrais para a preparacao de medicamentos
DE60122495D1 (de)	2006-10-05	TRANS-N-i4-(4-HYDROXYPHENYL)CYCLOHEXYLö-3-PHENYLPROPIONAMID ALS SUBTYP-SELEKTIVER NMDA REZEPTOR ANTAGONIST
ATE291900T1 (de)	2005-04-15	5ht1-rezeptoragonist enthaltendes arzneimittel
DK1068202T3 (da)	2009-03-16	1-(-heteroarylpropyl- eller -prop-2-enyl)-4benzylpipderidiner som NMDA-receptor-antagonister
MA26890A1 (fr)	2004-12-20	Metabolites agonistes/ antagonistes d'oestrogenes
DK1146874T3 (da)	2005-01-31	Vitronectinreceptoragonist
DE50206910D1 (de)	2006-06-29	Substituierte y-lactonverbindungen als nmda-antagonisten
NO20013978L (no)	2001-08-15	Dopamin D1 reseptor agonist forbindelser
DK1347760T3 (da)	2005-09-05	Farmaceutiske kompositioner med NMDA receptor agonister
FI20012242A0 (fi)	2001-11-19	Uudet farmaseuttiset yhdisteet
GB0130576D0 (en)	2002-02-06	Dopamine D1 receptor agonist pro-drug compounds & derivatives
SE0003996D0 (sv)	2000-11-01	Receptorantagonister
DK1450770T3 (da)	2005-08-01	Farmaceutisk præparat, der omfatter en 5HT1-receptoragonist
UA4167S (uk)	2000-12-15	Набір упаковок для ліків «метрозол»
LT2000015A (lt)	2001-02-26	Nesteroidiniai ligandai estrogeno receptoriui
SE0003995D0 (sv)	2000-11-01	Receptoragonister och antagonister